We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Blumenthal said the ABC structure originated in the 1999 ...

A risk calculator that incorporates established cardiovascular risk factors and additional cardiac biomarkers, such as high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type ...

A polypill that includes key medications associated with improved outcomes (aspirin, angiotensin-converting–enzyme [ACE] inhibitor, and statin) has been proposed as a simple approach to the secondary ...

Medscape: Why update the guidelines at this time? Dr. Epstein: At the time when the initial guidelines were written in 1996, the vast majority of ICDs were implanted for secondary prevention in people ...

Statins are widely used in the evidence-based lowering of cardiovascular disease (CVD) risk. The use of these drugs for secondary prevention of CVD is well founded, but their expanding use in primary ...

Objective: To apply the UK Medical Research Council (MRC) framework for development and evaluation of trials of complex interventions to a primary healthcare intervention to promote secondary ...

The balance of benefits and risks of aspirin in primary prevention is far less clear than in secondary prevention; further data from randomized trials of individuals at intermediate cardiovascular ...

Once-daily asundexian 50 mg, on top of antiplatelet therapy, reduced risk for recurrent ischemic stroke after a ...

The original study included 309,056 subjects with type 2 diabetes from the United States and five European countries. A 51% relative risk reduction (RRR) in all-cause mortality was observed in favor ...

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management ...

Ultimately, investigators found a significant reduction in ischemic stroke risk with asundexian compared to placebo, both in combination with antiplatelet therapy. Additionally, participants had no ...